Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosis

References

• Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• McElhiney MC, Rabkin JG, Gordon PH, Goetz R, Mitsumoto H. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009;80:1146.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:381.
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, et al. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurol Sci. 2015;36:2243–52.
   PubMed Web of Science ®Google Scholar
• Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration. Chest. 1993;103:508–13.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390–2.
   PubMed Web of Science ®Google Scholar
• Kirk SE, Tracey TJ, Steyn FJ, Ngo ST. Biomarkers of metabolism in amyotrophic lateral sclerosis. Front Neurol. 2019;10:191.
   PubMed Web of Science ®Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   Google Scholar
• Fang L, Huber-Abel F, Teuchert M, Hendrich C, Dorst J, Schattauer D, et al. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2009;285:62–6.
   Google Scholar
• Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tökés ZA. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochemi. 1996;67:251–9.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Munakata S, Takahashi K, Kanda F, Hashimoto K, et al. Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. J Neurol Sci. 1998;160:140–7.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Tsumura M, Takahashi K, Jinnai K, Suzuki M, et al. Increased serum hyaluronic acid in amyotrophic lateral sclerosis: relation to its skin content. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:213–8.
   PubMed Web of Science ®Google Scholar
• Ono S, Mechanic GL, Yamauchi M. Amyotrophic lateral sclerosis: unusually low content of collagen in skin. J Neurol Sci. 1990;100:234–7.
   PubMed Web of Science ®Google Scholar
• Laurent TC, Fraser JRE. Hyaluronan. FASEB J. 1992;6:2397–404.
   PubMed Web of Science ®Google Scholar
• KjAER M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev. 2004;84:649–98.
   PubMed Web of Science ®Google Scholar
• Nagy N, Sunkari VG, Kaber G, Hasbun S, Lam DN, Speake C, et al. Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control. Matrix Biol. 2019;80:46–58.
   PubMed Web of Science ®Google Scholar
• Lebel L. Clearance of hyaluronan from the circulation. Adv Drug Deliv Rev. 1991;7:221–35.
   Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci. 1994;124: 96–107.
   PubMed Web of Science ®Google Scholar
• Steyn FJ, Ioannides ZA, van Eijk RPA, Heggie S, Thorpe KA, Ceslis A, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89:1016–23.
   PubMed Web of Science ®Google Scholar
• Fraser JRE, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Int Med. 2005;258:460–6.
   PubMed Web of Science ®Google Scholar
• Rössler A, László Z, Kvas E, Hinghofer-Szalkay HG. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. Eur J Appl Physiol Occup Physiol. 1998;78:573–7.
   PubMed Web of Science ®Google Scholar
• Berg S, Brodin B, Hesselvik F, Laurent TC, Maller R. Elevated levels of plasma hyaluronan in septicaemia. Scand J Clin Lab Invest. 1988;48:727–32.
   PubMed Web of Science ®Google Scholar
• Engströum-Laurent, Anna, Hällgren, Roger. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness. Arthritis Rheum. 1987;30:1333–8.
   PubMedGoogle Scholar
• Criscione LG, Elliott AL, Stabler T, Jordan JM, Pieper CF, Kraus VB. Variation of serum hyaluronan with activity in individuals with knee osteoarthritis. Osteoarthr Cartil. 2005;13:837–40.
   PubMed Web of Science ®Google Scholar
• Ono S, Toyokura Y, Mannen T, Ishibashi Y. “Delayed return phenomenon” in amyotrophic lateral sclerosis. Acta Neurol Scand. 1988;77:102–7.
   PubMed Web of Science ®Google Scholar
• Ngo ST, van Eijk RPA, Chachay V, van den Berg LH, McCombe PA, Henderson RD, et al. Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:497–505.
   PubMed Web of Science ®Google Scholar